JPRN-UMIN000003114已完成未知
A phase II trial of neoadjuvant imatinib for large gastric GIST in Japan and Korea - A phase II trial of neoadjuvant imatinib for large gastric GIST
Japanese Study Group on GIST0 个研究点目标入组 55 人开始时间: 2010年1月28日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Patients who have a medical history of active double cancers in the past 5 years 2)Patients who have a medical history of GIST 3)Patients who have heart disease of NYHA (New York Heart Association) class III or IV 4)Patients who are pregnant, lactating, or with the intention of becoming pregnant (including men) 5)Patients who have uncontrollable diseases or serious complications
研究者
相似试验
招募中
不适用
A phase 2 study of 5 years of adjuvant imatinib in patients with gastrointestinal stromal tumor with a high risk of recurrence following surgical resectioNeoplasmsKCT0007371Asan Medical Center35
已完成
不适用
Open-label, multicenter phase II study of imatinib mesylate in patients with steroid-refractory chronic graft-versus-host diseaseKCT0006785Kyungpook National University Hospital39
进行中（未招募）
1 期
A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST)unresectable metastatic GISTMedDRA version: 20.0 Level: LLT Classification code 10062427 Term: Gastrointestinal stromal tumor System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10051066 Term: Gastrointestinal stromal tumour System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-001298-42-GBEuropean Organisation for Research and Treatment of Cancer76
进行中（未招募）
不适用
A randomised phase II trial of imatinib alternating withregorafenib compared to imatinib alone for the first linetreatment of advanced gastrointestinal stromal tumour (GIST)unresectable metastatic GISTMedDRA version: 18.0Level: LLTClassification code 10062427Term: Gastrointestinal stromal tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: PTClassification code 10051066Term: Gastrointestinal stromal tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-001298-42-ESEuropean Organisation for Research and Treatment of Cancer240
进行中（未招募）
1 期
A randomised phase II trial of imatinib alternating withregorafenib compared to imatinib alone for the first linetreatment of advanced gastrointestinal stromal tumour (GIST)unresectable metastatic GISTMedDRA version: 18.0Level: LLTClassification code 10062427Term: Gastrointestinal stromal tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: PTClassification code 10051066Term: Gastrointestinal stromal tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-001298-42-NOEuropean Organisation for Research and Treatment of Cancer240